Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q→R genetic polymorphism

Journal of Lipid Research

Volumn 40, Issue 1, 1999, Pages 133-139

  Cao, Huibi ^a   Girard Globa, Anik ^a   Berthezene, Francois ^b   Moulin, Philippe ^a,b  

^a UNIVERSITÉ LYON 1   (France)

^b Hopital de l'Antiquaille   (France)

Author keywords

Atherosclerosis; HDL; LDL; Paraoxonase; Peroxidation

Indexed keywords

ARYLDIALKYLPHOSPHATASE; EDETIC ACID; ESTERASE; HIGH DENSITY LIPOPROTEIN; LIPID PEROXIDE; LOW DENSITY LIPOPROTEIN; PARAOXON;

ADULT; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROPHORETIC MOBILITY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME ASSAY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; LIPID PEROXIDATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; THERMOSTABILITY;

EID: 0032945537     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-2275(20)33348-4     Document Type: Article

References (36)

1. Steinberg, D. 1997. Low density lipoprotein oxidation and its pathobiological significance. J. Biol. Chem. 272: 20963-20966.
2. Ylä-Herttuala, S., W. Palinski, M. E. Rosenfeld, S. Parthasarathy, T. E. Carew, S. Butler, J. L. Witztum, and D. Steinberg. 1989. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and human. J. Clin. Invest. 84: 1086-1095.
3. Andrews, B., K. Burnand, G. Paganga, N. Browse, C. Rice-Evans, K. Sommerville, D. Leake, and N. Taub. 1995. Oxidisability of low density lipoproteins in patients with carotid or femoral artery atherosclerosis. Atherosclerosis. 112: 77-84.
4. Halevy, D., J. Thiery, D. Nagel, S. Arnold, E. Erdmann, B. Höfling, P. Cremer, and D. Seidel. 1997. Increased oxidation of LDL in patients with coronary artery disease is independent from dietary vitamins E and C. Arterioscler. Thromb. Vasc. Biol. 17: 1432-1437.
5. Berliner, J. A., M. Navab, A. M. Fogelman, J. S. Frank, L. L. Demer, P. A. Edwards, A. D. Watson, and A. L. Lusis. 1995. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation. 91: 2488-2496.
6. Stephens, N. G., A. Parsons, P. M. Schofield, F. Kelly, K. Cheeseman, M. J. Mitchison, and M. J. Brown. 1996. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 347: 781-786.
7. Halliwell, B. 1994. Free radicals, antioxidants, and human disease. Lancet. 344: 721-724.
8. Furlong, C. E., L. G. Costa, C. Hassett, R. J. Richter, J. A. Sundstrom, D. A. Adler, C. M. Disteche, C. J. Omiecinski, C. Chapline, J. W. Crabb, and R. Humbert. 1993. Human and rabbit paraoxonase: purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification. Chem. Biol. Interact. 87: 35-48.
9. Mackness, M. I., S. Arrol, and P. N. Durrington. 1991. Paraoxonase prevents accumulation of lipoperoxide in low-density lipoprotein. FEBS. 286: 152-154.
10. Mackness, M. I., S. Arrol, C. Abbott, and P. N. Durrington. 1993. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 104: 129-135.
11. Parthasarathy, S., J. Barnet, and L. G. Gong. 1990. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim. Biophys. Acta. 1044: 275-283.
12. Suc, I., I. Escargueil-Blanc, M. Troly, R. Salvayre, and A. Nègre-Salvayre. 1997. HDL and apoA prevent cell death of endothelial cell induced by oxidized LDL. Arterioscler. Thromb. Vasc. Biol. 17: 2158-2166.
13. Watson, A. D., J. A. Berliner, S. Y. Hama, B. N. La Du, K. F. Faull, A. M. Fogelman, and M. Navab. 1995. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96: 2882-2891.
14. Van Lenten, B. J., S. Y. Hama, F. C. de Beer, D. M. Stafforini, T. M. McIntyre, S. M. Prescott, B. N. La Du, A. M. Fogelman, and M. Navab. 1995. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cultures. J. Clin. Invest. 96: 2758-2707.
15. Humbert, R., D. A. Adler, C. M. Disteche, C. Hassett, C. J. Omiecinski, and C. E. Furlong. 1993. The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genet. 3: 73-76.
16. Adkins, S., K. N. Gan, M. Mody, and B. N. La Du. 1993. Molecular basis for the polymorphic forms of human serum paraoxonase/ arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am. J. Hum. Genet. 52: 598-608.
17. Nevin, D. N., A. Zambon, C. E. Furlong, R. J. Richter, R. Humbert, J. E. Hokanson, and J. D. Brunzell. 1996. Paraoxonase genotypes, lipoprotein lipase activity, and HDL. Arterioscler. Thromb. Vasc. Biol. 16: 1243-1249.
18. Blatter Garin, M. C., R. W. James, P. Dussoix, H. Blanché, P. Passa, P. Froguel, and J. Ruiz. 1997. Paraoxonase polymorphism Met-Leu 54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased cardiovascular risk in diabetes. J. Clin. Invest. 99: 62-66.
19. Ruiz, J., H. Blanché, R. W. James, M-C. S. Garin, C. Vaisse, G. Charpentier, N. Cohen, A. Morabia, P. Passa, and P. Froguel. 1995. Gln-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. 346: 869-872.
20. Serrato, S., and A. J. Marian. 1995. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J. Clin. Invest. 96: 3005-3008.
21. Sanghera, D. K., N. Saha, C. E. Aston, and M. I. Kamboh. 1997. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 17: 1067-1073.
22. Odawara, M., Y. Tachi, and K. Yamashita. 1997. Paraoxonase polymorphism (Gln 192-Arg) is associated with coronary heart disease in Japanese non-insulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 82: 2257-2260.
23. Antikainen, M, S. Murtomāki, M. Syvänne, R. Pahlman, E. Tahvanainen, M. Jauhianen, M. H. Frick, and C. Ehnholm. 1996. The Gln-Arg 191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J. Clin. Invest. 98: 883-885.
24. Herrmann, S. M., H. Blanc, O. Poirier, D. Arveiler, G. Luc, A. Evans, P. Marques-Vidal, J. M. Bard, and F. Cambien. 1996. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM study. Atherosclerosis. 126: 299-303.
25. Suehiro, T., Y. Nakauchi, M. Yamamoto, K. Arii, H. Itoh, N. Hammashige, and K. Hashimoto. 1996. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int. J. Cardiol. 57: 69-73.
26. Cao, H. B., A. Girard-Globa, A. Serusclat, S. Bernard, P. Bondon, S. Picard, F. Berthezene, and P. Moulin. 1998. Lack of association between carotid intima-media thickness and paraoxonase gene polymorphism in non-insulin-dependent diabetes mellitus. Atherosclerosis. 138: 361-366.
27. Aviram, M., M. Rosenblat, C. L. Bisgaier, R. S. Newton, S. L. Primo-Parmo, and B. N. La Du. 1998. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. J. Clin. Invest. 101: 1581-1590.
28. Mackness, M. I., S. Arrol, B. Mackness, and P. N. Durrington. 1997. Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation. Lancet. 349: 851-852.
29. Mackness, B., M. I. Mackness, S. Arrol, W. Turkie, and P. N. Durrington, 1998. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS. 423: 57-60.
30. Gan, K. N., A. Smolen, H. W. Eckerson, and B. N. La Du. 1991. Purification of human serum paraoxonase/arylesterase: evidence for one esterase catalyzing both activities. Drug. Metab. Disp. 19: 100-106.
31. El-Saadani, M., H. Esterbauer, M. El-Sayed, M. Goher, A. Y. Nassar, and G. Jürgens. 1989. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J. Lipid Res. 30: 627-630.
32. Mashima, R., Yamamoto Y., and S. Yoshimura. 1998. Reduction of phosphatidyl choline hydroperoxide by apolipoprotein A-I: purification of the hydroperoxide reducing proteins from human blood plasma. J. Lipid Res. 39: 1133-1140.
33. Garner, B., A. R. Waldeck, P. K. Witting, K. A. Rye, and R. Stoker. 1998. Oxidation of high density lipoproteins. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins A-I and A-II. J. Biol. Chem. 273: 6088-6095.
34. Kelso, G. J., W. D. Stuart, R. J. Richter, C. E. Furlong, T. C. Jordan-Starck, and J. A. Harmony. 1994. Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry. 33: 832-839.
35. Navab, M., S. Hama-Levy, B. J. Van Lenten, G. C. Fonarow, C. J. Cardinez, L. W. Castellani, M-L. Brennan, A. J. Lusis, and A. M. Fogelman. 1997. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J. Clin. Invest. 99: 2005-2019.
36. Castellani, L. W., M. Navab, B. J. Van Lenten, C. C. Hedrick, S. Y. Yama, A. M. Gotto, A. M. Fogelman, and A. J. Lusis. 1997. Overexpression of apolipoprotein A-II in transgenic mice converts high density lipoproteins to proinflammatory particles. J. Clin. Invest. 100: 464-474.